Avidicure develops Actibody, a proprietary triple‑agonistic antibody platform that simultaneously delivers primary activation, co‑stimulatory, and cytokine signals to immune cells, enabling sustained and localized immune activation. By genetically fusing engineered domains onto a human IgG scaffold and using AI‑driven in‑silico design, the molecules provide conditional activation at the target site, enhancing potency while reducing systemic toxicity for oncology and autoimmune applications.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
4OELFounders
Product
Problem
Current antibody therapeutics activate only one or two immune signaling pathways, providing insufficient activation of immune effector cells and leading to limited potency, rapid exhaustion, and poor durability in cancer and autoimmune indications.
Solution
Avidicure’s proprietary Actibody platform creates triple‑agonistic antibodies that simultaneously deliver the primary activation signal (Signal 1), a co‑stimulatory signal (Signal 2), and a cytokine signal (Signal 3) to immune cells. By genetically fusing two engineered domains onto a human IgG scaffold, the Actibody provides all three signals only when the antibody engages a target cell, ensuring localized activation and reducing systemic toxicity. AI‑driven in‑silico design optimizes the co‑stimulatory and cytokine domains for maximal efficacy while preserving target specificity. The resulting molecules sustainably stimulate both innate and adaptive immunity, enhancing proliferation, survival, and resistance of immune cells within the tumor micro‑environment, thereby converting immunologically “cold” tumors into “hot” ones and enabling potent, antigen‑independent tumor killing.
Target Audience
Primary customers are pharmaceutical and biotech companies developing immunotherapies for oncology and autoimmune diseases that require robust, durable immune activation.
Features
- Triple‑agonistic design delivering Signal 1 (Fc receptor/TCR), Signal 2 (e.g., 41BB or CD28), and Signal 3 (IL‑2/IL‑15/IL‑21) in a single antibody
- Conditional activation: co‑stimulatory and cytokine domains become functional only within the immunological synapse with target cells
- AI‑guided in‑silico optimization of the fused domains for potency, specificity, and safety
- Human IgG scaffold enables scalable, cost‑effective manufacturing using established antibody production platforms
- Engineered to enhance immune cell proliferation, survival, and resistance to immunosuppressive tumor micro‑environments
- Applicable across oncology (including AML, solid tumors) and autoimmune disease indications